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ae are daunted by the challenge of attempting to summa-
ize the important scientific observations in the field of
nterventional cardiology for the year 2003. Few other fields
f clinical science evolve as quickly as this one. Not only are
linicians inundated with publications and peer review
ournals, but also late-breaking trials are presented at major
eetings (Table 1). Internet web sites further disseminate
arly presentation of trials, and even pharmaceutical com-
any yearly reports are used as a method for disseminating
rial results. It would be pointless to simply abstract all
ources of information in this review. Rather, we have
hosen to highlight certain areas and studies that we believe
ill stand the test of time as important contributions in the
eld. In the end, we hope this review will provide non-
nterventionalists with a working knowledge of advances in
he field. For interventionalists, we have attempted to
ollate trials and findings into major categories as a frame-
ork for more in-depth study. We believe 2003 will be
emembered as the year of drug-eluting stents (DES) and
echanical reperfusion therapy for ST-segment elevation
yocardial infarction (STEMI). For this reason, we have
hosen to highlight these areas. In addition, adjunctive
harmacology, new devices, and important mechanistic
tudies will be summarized. Finally, we will point out the
uture trials that will be highlighted in the year 2004. We
ish to acknowledge the brilliance and perseverance of the
nvestigators who have made this review possible.
CUTE MYOCARDIAL INFARCTION (AMI)
he reperfusion wars of the last decade seem a distant
emory. Numerous data, including a recent overview of 23
andomized trials, clearly support the superiority of
atheter-based reperfusion over fibrinolytic therapy for the
reatment of STEMI (1,2) (Fig. 1). A recent analysis of the
ational Registry of Myocardial Infarction trials has also
emonstrated a mortality benefit with primary percutaneous
oronary intervention (PCI) in STEMI patients who have
ontraindications to thrombolytic therapy (3). Accordingly,
he focus of clinical research in AMI has been directed
oward several key issues: 1) how to improve the availability
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ptimal preprocedural therapy before primary PCI; and 3)
hat adjunctive therapies can be applied to enhance myo-
ardial salvage (Table 2)?
xpanding the benefit of mechanical reperfusion. Two
andmark studies published this year stole the spotlight:
he DANish trial in Acute Myocardial Infarction
DANAMI-2) and PRimary Angioplasty in acute myocar-
ial infarction patients from General community hospitals
ransported to percutaneous transluminal coronary angio-
lasty Units versus Emergency thrombolysis (PRAGUE-2)
4,5). The results of these trials have already had an
mportant impact on clinical practice patterns in North
merica. Both studies were designed to evaluate the opti-
al reperfusion strategy for patients presenting to hospitals
ithout invasive facilities. Patients were treated either
n-site with fibrinolysis (tissue-type plasminogen activator
t-PA] in DANAMI-2 and streptokinase in PRAGUE-2)
r transferred to an invasive center for emergency cardiac
atheterization and coronary intervention, when indicated.
n both trials, there was a dramatic reduction in the
ncidence of major adverse cardiac events (MACE) at 30
ays in the invasive groups; in fact, the DANAMI-2 trial
as halted early by the Data Safety and Monitoring Board
ecause of the marked improvement in outcome in patients
reated with mechanical reperfusion.
Therefore, these data validate the hypothesis that transfer
or catheter-based reperfusion is superior to on-site fibrino-
ytic therapy, despite the additional time to treatment
ncurred during patient transfer. This benefit is partly
xplained by the fact that stenting, unlike thrombolysis,
esults in greater myocardial salvage, independent of the
ime to treatment (6). Additionally, primary PCI signifi-
antly reduces the risk of early re-infarction, which is
ssociated with increased mortality after fibrinolytic therapy
7). In a recent meta-analysis of six randomized trials,
atient transfer for PCI was associated with a 42% reduction
n the composite end point (death/re-infarction/stroke),
ompared with a strategy of on-site thrombolysis (8). This
as driven mainly by a reduction in the incidence of
e-infarction (68% reduction) and stroke (56% reduction),
ut there was also a trend toward improved survival with
CI. Overall, these findings strongly support community-
ide adoption of a transfer strategy for mechanical reper-
usion. The challenge now is to overcome logistical obstacles
nd replicate these impressive results in routine clinical
ractice.
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Year in Interventional Cardiology March 3, 2004:875–90Immediate patient transfer for coronary intervention also
ppears to be beneficial for those patients who receive
ull-dose fibrinolytic therapy as the initial reperfusion strat-
gy. Current clinical guidelines discourage routine coronary
ntervention immediately after thrombolysis because of
istorical (but outdated) studies, suggesting an excess risk in
hese patients (9–11). With this in mind, the results of the
treptokinase In Acute Myocardial infarction (SIAM-III)
rial are timely (12). After full-dose reteplase, patients
dmitted to a community hospital were randomly assigned
o immediate PCI (within 6 h) or delayed intervention (at 2
eeks). Immediate stenting was associated with a significant
eduction in the composite clinical end point and improved
eft ventricular function at six months. More importantly,
here was no clear “downside” to immediate intervention in
erms of angiographic outcomes or major bleeding.
ptimizing preprocedural therapy. Given the inherentable 1. Glossary of Interventional Cardiology Trials in 2003
Acronym Trial
CE Abciximab and Carbostent Evaluation
DMIRE AmP579 Delivery for Myocardial Infarction REduction
SPECT ASian Paclitaxel-Eluting stent Clinical Trial
TLAS Acolysis during Treatment of Lesions Affecting Saphenous vein bypass grafts
RAVE Bavarian Reperfusion AlternatiVes Evaluation
OMMA COMplement inhibition in Myocardial infarction treated with Angioplasty
ONTRAST Prospective, Randomized, Placebo-Controlled, Multicenter Trial Evaluating Fenoldopam Mesylate for the Prevention of
Contrast-Induced Nephropathy
OOL-MI COOLing as an adjunctive therapy to percutaneous intervention in patients with acute Myocardial Infarction
REST Cilostazol for REStenosis Trial
RUISE Coronary Revascularization Using Integrilin and Single-bolus Enoxaparin study
ANAMI-2 DANish multicenter randomized study on thrombolytic therapy versus acute coronary angioplasty in Acute Myocardial
Infarction
ELIVER Randomized Comparison of Paclitaxel-Coated versus Metallic Stents for Treatment of Coronary Lesions
NDEAVOR Pilot Trial of the ABT-578–Coated Driver Stent in De Novo Coronary Lesions
-SIRIUS Sirolimus-Eluting Stents for Treatment of Long Atherosclerotic Lesions in Small Coronary Arteries
IRE FilterWire EX Randomized Evaluation
UTURE-II Multicenter Evaluation of the Bioabsorbable Polymer-Based Everolimus-Eluting Stent
RACIA-2 Grupo de Analisis de la Cardiopatia Isque´mica Aguda
OPE Hepacoat and an Antithrombotic Regimen of Aspirin Alone
SAR-REACT Intracoronary Stenting and Antithrombotic Regimen–Rapid Early Action for Coronary Treatment
ICE-3 National Investigators Collaborating on Enoxaparin-3
N-TIME Ongoing Tirofiban in Myocardial infarction Evaluation
RAGUE-2 PRimary Angioplasty in acute myocardial infarction patients from General community hospitals transported to percutaneous
transluminal coronary angioplasty Units vs Emergency thrombolysis
RONTO Plavix Reduction Of New Thrombus Occurrence
APPID RApid Protocol for the Prevention of contrast-Induced renal Dysfunction
ECOVERS Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts
EPLACE-2 Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to reduced Clinical Events
IAM-III South West German Interventional Study in Acute Myocardial Infarction
IRIUS Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients With De Novo Coronary Artery Lesions
TING STents IN Grafts
AXUS-IV Prospective, Multicenter, Randomized Trial of the Polymer-Based Paclitaxel-Eluting Stent in Patients With De Novo Lesions
IGER-PA TIrofiban Given in the Emergency Room before Primary Angioplasty
RAP A Randomized, Controlled, Multicenter Trial of Saphenous Vein Graft Intervention With or Without Distal Protection Using
the TRAP Vascular Filtration System
AMINE X-Sizer in AMI patients for Negligible Embolization and optimal ST-resolution
-TRACT X-SIZER for TReatment of thrombus and Atherosclerosis in Coronary interventions Trialigure 1. Short-term clinical outcomes in individuals treated with percu-
aneous transluminal coronary angioplasty (PTCA) or thrombolytic ther-
py, according to the type of thrombolytic agent used. Odds ratios and 95%
onfidence intervals are shown. (Reprinted from Keeley et al. [1], withime delay associated with patient transfer, there has been a
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March 3, 2004:875–90 Year in Interventional Cardiologyable 2. Interventional Trials in Acute Myocardial Infarction
Study Study Design n
Primary Study
End Point Principal Results
atient transfer
DANAMI-2 (4) AMI 12 h; randomized to t-PA or PCI 1,572 Composite death,
re-infarction, stroke
at 30 days
Primary end point lower in PCI group
(8.5% vs. 14.2%, p  0.002)
PRAGUE-2 (5) AMI 12 h; randomized to thrombolysis
or transfer for primary PCI
850 30-day mortality Mortality 10.0% in thrombolytic group vs.
6.8% in PCI group (p  0.12); MACE
(death/re-infarction/stroke) lower in PCI
group (8.4% vs. 15.2%, p  0.05)
SIAM-III (12) AMI 12 h; all patients received t-PA;
randomized to immediate stenting (6
h) or delayed stenting (2 weeks)
197 Composite death, re-
infarction, ischemic
events, TLR at 6
months
Significant reduction of combined end
point: 25.6% vs. 50.6%, p  0.001)
acilitated PCI
BRAVE (15)* AMI 12 h; randomized to pretreatment
with abciximab alone or half-dose
reteplase  abciximab
253 Infarct size by SPECT
imaging
Higher incidence of initial TIMI flow grade
3 in reteplase plus abciximab group, but
no difference in final infarct size (13% vs.
11.5%, p  NS)
GRACIA-2 (14)* AMI 12 h; randomized to immediate
PCI or immediate thrombolysis (TNK–
t-PA) followed by early angiography
(3–12 h)
212 Infarct size (CK AUC),
ST-segment
resolution, LV
function
No difference in infarct size or LV
function; higher incidence of complete
ST-segment resolution in facilitated arm
(61% vs. 43%, p  0.03)
ON-TIME (19)* AMI 6 h; randomized to receive
tirofiban early (ambulance or referral
center) or late (in catheterization
laboratory)
487 Incidence TIMI flow
grade 3 at initial
angiography
TIMI flow grade 3 similar (19% vs. 15%
but higher incidence TIMI flow grade 2
in early group (43% vs 34%, p  0.04)
TIGER-PA pilot (20) AMI 12 h; randomized to early
tirofiban (in emergency room) or
tirofiban in catheterization laboratory
100 TIMI grade flow, cTFC,
TMPG
Improved initial TIMI flow grade, frame
count, and TMPG in early tirofiban
group
djunctive therapies
ADMIRE (22) AMI 6 h; randomized to placebo
or one of three doses of AmP579
(a mixed adenosine agonist)
311 Infarct size by SPECT
imaging
No difference in final infarct size among
placebo or active treatment groups. Trend
toward greater salvage in treated patients
with anterior MI
COMMA (21) AMI 6 h; randomized to PCI with
pexelizumab (bolus alone or bolus plus
infusion) vs. PCI alone
960 Infarct size by CK-MB
area under the curve
No difference between groups (placebo
median: 4,393; bolus pexelizumab: 4,526;
bolus  infusion: 4,713 ng/ml). Lower
mortality at 90 days in bolus  infusion
group
COOL-MI (24)* AMI 6 h; randomized to PCI with
mild hypothermia or PCI alone
395 Infarct size by SPECT
imaging
Overall no difference in infarct size (median
10% of LV in each group), but smaller
MI size in anterior MI group if
adequately cooled at reperfusion
Glucose-insulin-
potassium study
(23)
AMI 24 h; randomized to continuous
infusion of glucose-insulin-potassium
or no infusion
940 30-day mortality No difference in overall mortality (4.8%
with GIK vs. 5.8%); in patients without
heart failure (Killip class I), lower
mortality observed (1.2% vs. 4.2%)
djunctive devices
Napodano et al. (25) AMI 12 h; angiographic thrombus, and
TIMI flow grade 2; randomized to
thrombectomy with stenting or stenting
alone
92 Postprocedural TMPG-3 Higher incidence of normal myocardial
perfusion (TMPG-3) after stenting in
thrombectomy group (71.7% vs. 36.0%,
p  0.006).
XAMINE-ST (26) AMI 12 h; TIMI flow grade 0 or 1 at
baseline; randomized to stenting with
or without thrombectomy using the
X-SIZER device
201 ST-segment resolution More complete ST-segment resolution and
lower incidence of distal embolization in
the X-SIZER group
Limbruno et al. (27) AMI 6 h and TIMI flow grade 3
undergoing PCI with FilterWire
device; case-matched comparison
100 Safety and feasibility of
adjunctive FilterWire
use
Use of FilterWire safe during PCI; lower
cTFC and higher TMPG after PCI in
FilterWire group
Trial presented at scientific meeting but not yet published.
AMI  acute myocardial infarction; AUC  area under the curve; CK-MB  creatine kinase, MB fraction; cTFC  corrected TIMI frame count; GIK 
lucose-insulin-potassium; LV  left ventricle or ventricular; PCI  percutaneous coronary intervention; MACE  major adverse cardiac events; SPECT  single-photon
mission computed tomography; TIMI  Thrombolysis in Myocardial Infarction trial; TLR  target lesion revascularization; TMPG  TIMI myocardial perfusion grade;
NK  tenecteplase; t-PA  tissue-type plasminogen activator; for acronyms, see Table 1.
r
m
r
h
c
[
v
o
s
A
t
(
r
i
i
m
a
b
R
p
i
b
t
t
f
t
h
fl
s
t
M
i
a
i
m
h
a
s
c
c
c
c
t
p
c
v
D
f
i
t
I
f
a
M
b
p
r
e
s
l
m
s
T
e
b
a
A
s
j
T
p
o
f
f
m
t
d
i
i
t
a
b
c
i
s
p
b
m
(
i
m
u
t
f
e
w
t
b
f
g
w
t
w
f
i
g
s
878 O’Neill and Dixon JACC Vol. 43, No. 5, 2004
Year in Interventional Cardiology March 3, 2004:875–90esurgence of interest in combining pharmacologic and
echanical reperfusion strategies in patients with AMI,
ecently termed the “pharmacoinvasive approach” (13). The
ypothesis is that antecedent pharmacologic therapy (typi-
ally a fibrinolytic agent either alone or with a glycoprotein
GP] IIb/IIIa inhibitor) will partially recanalize the infarct
essel before PCI, thus improving angiographic and clinical
utcomes. Two studies evaluating this approach were pre-
ented in the latter half of the year. In the GRupo de
na´lisis de la Cardiopatia Isque´mica Aguda (GRACIA-2)
rial, patients were randomized to a strategy of primary PCI
with abciximab) or immediate tenecteplase plus enoxapa-
in, followed by early angiography (within 3 to 12 h) and
ntervention, if indicated (14). There was no difference in
nfarct size or left ventricular function (at 6 weeks); however,
ore patients had complete ST-segment resolution (70%)
t 6 h in the “facilitated” group. The incidence of major
leeding was similar in each group. In contrast, the Bavarian
eperfusion AlternatiVes Evaluation (BRAVE) trial com-
ared combination therapy (half-dose reteplase and abcix-
mab) with abciximab alone, followed by immediate PCI, in
oth treatment groups (15). Seventy-four percent of pa-
ients presented to a non-PCI center (mean transfer dis-
ance of 39 km). Initial Thrombolysis In Myocardial In-
arction trial (TIMI) flow grade 3 was significantly higher in
he combination therapy group (40% vs. 18%, p  0.001);
owever, there was no difference in the incidence of TIMI
ow grade 3 after PCI. The primary end point of the
tudy—infarct size by single-photon emission computed
omographic imaging—was similar in both study groups.
oreover, there was a higher rate of complications, includ-
ng major bleeding, in patients treated with reteplase plus
bciximab. Overall, these data suggest that the pharmaco-
nvasive approach is not superior to primary PCI alone when
echanical intervention can be performed rapidly after
ospital presentation. On the other hand, the facilitated
pproach with thrombolytic pre-treatment should be con-
idered when a delay (3 h) is anticipated before cardiac
atheterization.
The optimal preprocedural therapy for patients in the
atheterization laboratory remains controversial (16). Re-
ently, Antoniucci et al. (17) found that abciximab de-
reased the primary end point (death, myocardial infarction,
arget vessel revascularization, stroke at one month) in 400
atients randomized to PCI with or without abciximab. In
ontrast, the larger Controlled Abciximab and Device In-
estigation to Lower Late Angioplasty Complications (CA-
ILLAC) trial showed only a modest clinical benefit, so
urther trials will be required (18). Denigration or trumpet-
ng of previous negative or positive adjunctive abciximab
rials cannot resolve this controversy.
Other groups have investigated the role of early GP
Ib/IIIa inhibition alone (without fibrinolytic therapy) to
acilitate primary PCI outcomes. Two recent studies have
ddressed the issue of timing: the ONgoing Tirofiban inyocardial infarction Evaluation (ON-TIME) and TIrofi- wan Given in the Emergency Room before Primary Angio-
lasty (TIGER-PA) (19,20). In both studies, patients were
andomized to receive tirofiban early (ON-TIME started
ither in the ambulance or referral center; TIGER-PA
tarted in the emergency room) or in the catheterization
aboratory. Early tirofiban was associated with an improve-
ent in initial angiographic outcomes, but there was no
ignificant difference in final TIMI flow grade, corrected
IMI frame count, or blush score in either study. Thus,
arly administration of tirofiban before primary PCI is safe
ut appears to have only a modest benefit in terms of initial
ngiographic outcomes.
djunctive therapies and devices to enhance myocardial
alvage. The results of several studies evaluating new ad-
uncts to mechanical reperfusion were reported this year.
he common goal in each of these studies was to test new
harmacologic agents or devices that might limit the extent
f myocardial necrosis and thus preserve left ventricular
unction. Therapeutic targets included prevention of reper-
usion injury or distal embolization and modulation of
yocyte metabolism.
The COMplement inhibition in Myocardial infarction
reated with Angioplasty (COMMA) trial was performed to
etermine the effect of pexelizumab, a C5 complement
nhibitor, on infarct size (21). Complement activation is an
mportant mediator of inflammatory damage and is believed
o contribute to reperfusion injury. In the active treatment
rms, two dosing regimens were tested: bolus alone and
olus plus infusion. The primary end point—infarct size by
reatine kinase area-under-the-curve analysis—was similar
n each study group. However, there was an intriguing and
tatistically significant reduction in 90-day mortality in the
exelizumab bolus plus infusion group compared with the
olus alone or placebo group, suggesting that pexelizumab
ay be beneficial in this setting. A definitive mortality trial
Apex MI) will be conducted in patients with anterior wall
nfarction. Another pharmacologic agent, AmP579 (a
ixed adenosine agonist), was studied in 311 patients
ndergoing primary PCI; however, there was no effect of
he therapy on final infarct size in the AMP-579 Delivery
or Myocardial Infarction REduction (ADMIRE) trial (22).
There has been renewed interest in protecting the isch-
mic myocardium via metabolic modulation, in particular,
ith glucose-insulin-potassium (GIK) treatment. This
herapy has a number of beneficial effects at a cellular and
iochemical level, including shift of myocardial metabolism
rom free fatty acids to glucose oxidation and increased
lycolytic adenosine triphosphate synthesis. This therapy
as investigated in a large, randomized trial conducted by
he Zwolle group (23). A total of 940 patients with AMI
ere randomly assigned to either continuous GIK infusion
or 8 to 12 h or no infusion. Overall, there was no difference
n 30-day mortality (the primary end point) between study
roups; however, there was an impressive improvement in
urvival with GIK in the 856 patients who presented
ithout signs of heart failure (Killip class I) (1.2% vs. 4.2%,
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March 3, 2004:875–90 Year in Interventional Cardiology 0.01). Conversely, a higher mortality was seen in the
IK group in those with heart failure, possibly due to the
igh rate of GIK infusion. Further studies are currently
eing conducted to clarify the effects of GIK treatment in
yocardial infarction.
Myocardial cooling is a newer and innovative approach to
ardioprotection. Experimental studies have demonstrated
hat mild hypothermia reduces metabolic demand in the risk
egion and limits infarct size. Accordingly, the COOLing as
n adjunctive therapy to percutaneous intervention in pa-
ients with acute Myocardial Infarction (COOL-MI) inves-
igators sought to evaluate the effect of mild systemic
ypothermia during myocardial infarction (24). A total of
95 patients with AMI were assigned to primary PCI with
ypothermia or primary PCI alone. Hypothermia was
nduced using an endovascular cooling system with a target
emperature of 33°C. Cooling was found to be safe and well
olerated. At the time of PCI, the median reduction in core
emperature was approximately 1°C, which was less than
nticipated. The final infarct size at 30 days was similar in
oth study groups; however, there was a significant reduc-
ion in infarct size in patients with an anterior infarction
ho were adequately cooled at the time of reperfusion.
hese findings suggest that the heart needs to be cooled to
he target temperature (33°C) before reperfusion for hypo-
hermia to provide optimal myocyte protection. Further
tudies are planned to confirm these findings.
Embolization of thrombus and atherosclerotic plaque is
n important mechanism contributing to poor myocardial
erfusion after infarct artery angioplasty. Several techniques
re being studied to limit the effects of distal embolization,
ncluding the use of thrombectomy devices and distal
rotection systems. Two studies reported this year demon-
trated that patients treated with adjunctive thrombectomy
efore stenting have a lower incidence of angiographic
omplications, such as no-reflow and distal embolization,
nd better myocardial perfusion after PCI than patients
reated without thrombectomy (assessed by the degree of
T-segment resolution or TIMI myocardial perfusion
rade) (25,26). Improved angiographic outcomes have also
een reported with a filter-based distal protection system
27). Although larger trials are required to evaluate the effect
f thrombectomy on clinical outcomes, these data suggest
hat preventing distal embolization is an important ap-
roach during mechanical reperfusion. Results of the ran-
omized trial of AngioJet thrombectomy plus stent versus
tent alone (AIMI) and Enhance Myocardial Efficacy and
emoval by Aspiration of Liberated Debris (EMERALD)
GuardWire distal protection system) clinical trials will be
resented in early 2004.
linical outcomes. On another note, an important obser-
ational study was reported this year by the Zwolle group
egarding the impact of circadian variations on the outcome
f primary angioplasty (28). In this analysis of 1,702
onsecutive patients, those treated during off-hours had a
igher incidence of failed angioplasty (6.9% vs. 3.8%, p  i.01) and worse clinical outcome than those treated during
outine hours. The explanation for these findings is not
lear; however, these data have important implications for
nterventionalists, especially with the growing enthusiasm
or mechanical reperfusion as the primary therapeutic strat-
gy in myocardial infarction.
CUTE CORONARY SYNDROMES (ACS)
large body of evidence supports an early invasive approach
n intermediate- or high-risk patients with ACS (non-
TEMI/unstable angina). Data from the FRagmin during
nStability in Coronary artery disease (FRISC-II) Treat
ngina with Aggrastat and Determine Cost of Therapy
ith an Invasive or Conservative Strategy (TACTICS),
IMI-18, and Randomized Intervention Treatment of
ngina (RITA-3) trials clearly demonstrate improved clin-
cal outcomes with routine early cardiac catheterization and
evascularization, compared with a conservative strategy,
specially in those patients with ST-segment depression or
ositive biomarkers (29–31). More recently, ST-segment
levation in lead aVR has also been identified as a high-risk
eature in non-STEMI patients (32). Coupled with ad-
ances in adjunctive pharmacologic therapy and stent tech-
ology, the interventional community has rapidly adopted
arly intervention as the “standard-of-care” approach.
One of the key questions that emerged from these studies
as the optimal timing for intervention. For many years it
as been recognized that PCI in patients with ACS is
ssociated with an increased risk of periprocedural compli-
ations, such as distal embolization, no-reflow, and myo-
ardial infarction. Because of this hazard, it has been
uggested that “plaque passivation” with antiplatelet and
ntithrombotic treatment before coronary intervention
ight improve angiographic and clinical outcomes. This
ypothesis was formally tested in the Intracoronary Stenting
nd Antithrombotic Regimen (ISAR-COOL) trial (33). A
otal of 410 patients with unstable angina and ST-segment
epression or elevated troponin T levels were randomized to
arly intervention (within 6 h of presentation) or to a
cooling-off” strategy with antithrombotic pretreatment for
hree to five days before intervention. All patients received
spirin, clopidogrel (600-mg loading dose), intravenous
nfractionated heparin, and intravenous tirofiban. At 30
ays, the primary end point (a composite of death or large
yocardial infarction) was 11.6% in those receiving pro-
onged antithrombotic treatment and 5.9% in the early
ntervention group (relative risk 1.96, 95% confidence in-
erval [CI] 1.01 to 3.82; p  0.04). This difference was
riven mainly by an increased incidence of myocardial
nfarction before catheterization in the prolonged anti-
hrombotic group. Thus, early intervention with optimal
ntiplatelet therapy seems to be preferable to delayed
ntervention after several days and, notably, is not associated
ith an early procedural hazard. These data have importantmplications for the management of intermediate- and
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Year in Interventional Cardiology March 3, 2004:875–90igh-risk patients with ACS. Early intervention seems
ustified, both in terms of safety and clinical efficacy and,
oreover, is likely to result in significant cost savings to
ospitals and payors worldwide. Further data from the
ngoing Medicine vs. Angioplasty for Thrombolytic Exclu-
able 3. Drug-Eluting Stent Trials: Sirolimus/Everolimus
SIRIUS
rial design
Type of lesions De novo
Length of FU (months) 8/9
Vessel diameter (mm) 2.5–3.5
Target vessel length (mm) 15–30
Stent utilized Bx velocity
Stent size (mm) 2.5–3.5
Stent length (mm) 8, 18
Polymer PEVA  PBMA
Control DES p Va
rial arm
Number of patients 525 533
Drug coating — Sirolimus —
Drug dosing — 10 m mm2
Diabetics (%) 28 25 —
Complex lesions (B2/C) (%) 54 59 —
Mean lesion length (mm) 14.4 14.4 —
Stents per patient 1.4 1.4 —
8 Months
ngiographic data
Reference vessel diameter (mm) 2.81 2.78 0.3
Late loss in-stent (mm) 1.00 0.17 0.0
Late loss in-segment (mm) 0.81 0.24 0.0
Late loss index 0.61 0.1 0.0
Diameter stenosis at baseline (%) 65.5 65.1 0.4
Diameter stenosis at FU (%) 40.1 10.5 0.0
Restenosis, instent (%) 35.4 3.2 0.2
Proximal restenosis (%) 8.1 5.8 0.0
Distal restenosis (%) 7.2 2.0 —
Restenosis, in-segment (%) 36.3 8.9
VUS data
No. of patients 76 99 —
Neointimal volume (mm3) 56.8 4.1 0.0
Volume obstruction (%) 34.2 2.6 0.0
9 Months
linical data
Death (%) 0.6 0.9 0.7
MI (%) — — —
Q-wave MI 0.4 0.8 0.6
Non–Q-wave MI 2.9 2.1 0.4
CABG (%) 0.6 1.5 —
Thrombosis (all) (%) 0.8 0.4 —
Acute thrombosis, 24 h 0 0 —
Subacute thrombosis (1–30 days) 0.2 0.2 —
Late thrombosis (30 days) 0.6 0.2 —
TVR (all) at FU (%) 19.2 6.4 0.0
TLR (in lesion) at FU 16.6 4.1 0.0
TVR (remote) at FU 4.8 3.2 0.0
MACE at FU (%) 18.9 7.1 3.0
TVF (%) 21.0 8.6 —ions (MATE-2) trial are expected in 2005. sRUG-ELUTING STENTS
fter the initial euphoria created by the first-in-man expe-
ience (34) and the RAndomized study with the sirolimus-
luting Bx VELocity balloon-expandable stent (RAVEL)
E-SIRIUS ENDEAVOR
De novo De novo
8/9 4
2.5–3.0 3.0–3.5
15–32 15
Bx velocity Driver
2.5–3.0 3.0–3.5
8, 18 18
PEVA  PBMA PC coating
Control DES p Value Control DES p Value
177 175 0 100
— Sirolimus — — ABT-578 —
— 10 m mm2 — — 10 m mm2 —
27 19 0.076 NA 16 —
61 62 — — — —
15.1 14.9 — NA 10.9 —
1.5 1.6 — NA — —
8 Months 4 Months
2.55 2.55 — NA 2.96 —
1.05 0.2 0.001 NA 0.33 —
— — — NA 0.2 —
0.65 0.16 — NA 0.17 —
65.8 65.1 — NA 70.3 —
48.7 24.3 0.001 NA 14.4 —
42.3 3.9 0.001 NA 2.1 —
8.8 2.1 0.018 NA 0 —
11.0 2.0 0.001 NA 0 —
42.9 5.9 0.001 NA 2.1 —
— — — NA 98 —
— — — NA 6.1 —
— — — NA 4.5 —
9 Months 4 Months
0.6 1.1 0.622 NA 0 —
— — — NA 1 —
0 1.1 0.247 NA 0 —
2.3 3.4 0.541 NA 1.1 —
0 0 — NA — —
0 1.1 0.247 NA 1.0 —
0 0 — NA 0 —
0 1.1 0.247 NA 1.0 —
0 0 — NA 0 —
— — — NA — —
20.9 4.0 0.001 NA 1.0 —
— — — NA 0 —
22.8 8.0 0.001 NA 2.0 —
— — — NA — —
Continued on next pagelue
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hrough. These larger trials were published in the year 2003.
he Sirolimus-coated Bx velocity balloon-expandable stent
n the treatment of patients with de novo artery lesions
able 3 Continued
FUTURE-I
De novo
6
2.75–4.0
18
S-stent
2.5–4.0
14, 18
Bioabsorbable
ontrol DES p Value
15 27
— Everolimus —
— — —
0 4 —
13 26 NS
8.32 9.17 NS
— — —
6 Months
2.96 3.1 NS
0.86 0.11 0.0001
— 0.17 —
0.46 0.06 —
62.12 64.09 NS
27.2 2.7 0.001
9.1 0 NS
— — —
— — —
9.1 3.7 NS
11 24
— — —
22.4 2.9 0.001
6 Months
0.0 3.8 NS
0.0 0.0 NS
0.0 0.0 NS
0.0 0.0 NS
— — —
— — —
— — —
— — —
— — —
— — —
8.3 3.8 NS
— — —
7.7 7.7 NS
— — —
ABG  coronary artery bypass graft surgery; DES  drug-eluting stent; FU  follo
S  not significant; PBMA  poly n-butyl methacrylate; PEVA  polyethylene-
bbreviations and acronyms as in Tables 1 and 2.SIRIUS) trial (36) was the first large U.S. experience with ihe Cypher (Johnson & Johnson, Warren, New Jersey)
tent, and this trial was quickly followed by the large
uropean experience (37). In addition, the Medtronic
BT-578–eluting stent had preliminary results presented
FUTURE-II
De novo
6
2.75–4.0
18
S-stent
2.5–4.0
14, 18
Bioabsorbable
Control DES p Value
43 21
— Everolimus —
— — —
27.9 23.8 NS
41.9 59.1 NS
11.62 11.07 NS
— — —
6 Months
2.97 2.91 NS
0.85 0.12 0.0001
0.54 0.17 0.002
0.44 0.17 —
65.56 64.59 NS
30.35 2.94 0.0001
19.4 0 NS
— — —
— — —
30.6 4.8 0.04
19 29
— — —
22.6 1.1 0.0001
6 Months
0.0 0.0 —
2.5 0.0 NS
0 0.0 NS
2.5 0.0 NS
— — —
— — —
— — —
— 0.0 —
— — —
— — —
15.0 4.8 NS
— — —
17.5 4.8 NS
— — —
IVUS  intravascular ultrasound; MI  myocardial infarction; NA  not available;
l acetate; TVF  target vessel failure; TVR  target vessel revascularization; otherw-up;
co-vinyn 2003. Finally, the Guidant everolimus-eluting stent had
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Year in Interventional Cardiology March 3, 2004:875–90reliminary safety data presented (38) (Table 3). These trials
emonstrate that rapamycin and rapamycin analogues dra-
atically decrease fibrointimal hyperplasia in de novo cor-
nary lesions. Whether different stent designs, different
olymers, or different rapamycin compounds provide supe-
ior outcomes will remain to be determined by future
andomized, comparative trials. In addition, the Johnson &
ohnson program has further evaluated the efficacy of the
ypher stent in complex in-stent restenosis (39,40). These
wo studies treated a total of 41 patients. One repeat
ngioplasty and two deaths occurred at follow-up. As a
esult of these pilot trials, a larger multicenter, randomized
rial of the Cypher stent versus vascular brachytherapy for
n-stent restenosis (SISR trial) is being conducted in the
.S.
In 2003, the results in anatomic subgroups excluded from
he initial randomized trials were reported. Saia et al. (41)
eported on 89 patients with STEMI who were treated with
ypher stents. In-hospital mortality was 6.2%. No early or
ate stent thromboses were observed, and no patients pre-
ented with clinical or angiographic restenosis. Lemos et al.
42) reported on 198 patients with ACS who were treated
ith Cypher stents. The 30-day MACE (6.1% vs. 6.6%)
nd stent thrombosis (0.5% vs. 1.7%) were similar for
ypher and historical control patients. These two reports
uggest that treatment of thrombus-laden culprit lesions
ay be safe. Further expanding indications for DES use
ay include unprotected left main stenosis (43) and bifur-
ation lesions (44). Larger data sets will be required to assess
he safety and efficacy in these complex lesion subsets.
The year 2003 also brought forth the first systematic
eports of restenosis after Cypher stent implantation. Co-
ombo et al. (45) reported that 11 of 368 consecutive
atients had in-stent or in-segment restenosis. The pattern
f restenosis was focal, and all lesions were intra-stent.
imilarly, Lemos et al. (46) reported that after detailed,
ystematic ultrasound analysis, restenosis after Cypher stent
mplantation was predominately related to vessel trauma
utside the stented segment. These studies and analysis of
he E-SIRIUS trial suggest that stent implantation with
enerous coverage of lesion margins, has almost entirely
liminated in-segment restenosis. Importantly, a diffuse
roliferative pattern was not encountered in any of the
eported trials.
A second major alternative to the rapamycin-coated stent
as reported in 2003 (Table 4). The year 2003 initially
rought enthusiasm for a simple painting of paclitaxel on
he Supra G stent (Cook Inc., Bloomington, Indiana). The
Sian Paclitaxel-Eluting stent Clinical Trial (ASPECT)
ad clinical, angiographic, and intravascular ultrasound
ndings reported (47,48). Unfortunately, these trials could
ot be replicated in the U.S. pivotal trial sponsored by
uidant Corp. (Randomized Comparison of Paclitaxel-
oated versus Metallic Stents for Treatment of Coronary
esions [DELIVER] trial) (49). In contradistinction, the
rospective, multicenter, randomized trial of the polymer- iased paclitaxel-eluting stent in patients with de novo
esions (TAXUS) program from Boston Scientific, where
aclitaxel is eluted from a polymer matrix, has been quite
uccessful, and the results were presented in 2003. The
AXUS program from Boston Scientific generated reports
n the TAXUS I, TAXUS II, and TAXUS III trials
50–52). Importantly, TAXUS IV, a randomized paclitaxel
.S. trial, was presented in September 2003 and led to a
ood and Drug Administration (FDA) advisory panel
ecommendation for approval in November 2003 (53).
hus, it is likely that U.S. clinicians will have two types of
ES available for general use in 2004. With the likelihood
hat two competitive DES systems will be on the market in
he U.S., the year 2004 will bring enormous marketing
fforts to the forefront. Advocates of either system will
ttempt to point out differences in late loss index, differences
n subgroups such as diabetics, differences in late stent
alposition, and differences in stent deliverability. Many of
hese comparisons must await formalized comparative trials,
uch as the ongoing European randomized trial of Cypher
ersus TAXUS stent (REALITY) trial. For now, U.S.
atients and physicians will have two safe and extremely
ffective stent systems for prevention of in-stent restenosis.
THER CORONARY DEVICES
lthough the year has been dominated by interest in DES
echnology, the results of several clinical trials evaluating
ew coronary devices have also been reported (Table 5).
otably, these studies have all addressed new approaches in
he treatment of saphenous vein graft (SVG) disease, which
emains a significant challenge in clinical practice. Specifi-
ally, these new devices were designed to reduce the risk of
ither distal embolic complications or late restenosis.
istal embolic protection. The importance of distal pro-
ection during SVG intervention is well established. In the
aphenous vein graft Angioplasty Free of Emboli Random-
zed (SAFER) trial, there was a 50% relative reduction in
he incidence of MACE in patients treated with the
uardWire balloon occlusion and aspiration system, thus
etting a new standard in the treatment of vein graft disease
54). However, there are a number of disadvantages with
alloon occlusion systems, including relative complexity of
se and procedural ischemia. On the other hand, filters are
omewhat easier to use, as they are designed to capture
mbolic particles while maintaining continuous flow.
The results of two randomized trials investigating filter
evices in vein graft intervention were reported this year.
he FilterWire EX Randomized Evaluation (FIRE) trial
valuated the efficacy of the Boston Scientific FilterWire
X system, compared with the approved GuardWire bal-
oon occlusion and aspiration system (55). The FilterWire
X device consists of a 0.014-inch guide wire that has an
val-shaped loop at the distal end, supporting a porous
embrane filter. The primary end point of this non-nferiority trial (MACE at 30 days) occurred in 9.9% of
Table 4. Drug-Eluting Stent Trials: Paclitaxel
ASPECT TAXUS-I TAXUS-II TAXUS-IV
Trial design
Type of lesions De novo De novo De novo De novo
Length of FU (months) 6 6 6 9
Vessel diameter (mm) 2.5–3.5 3.0–3.5 3.0–3.5 2.5–3.5
Target vessel length (mm) 12 10–28
Stent utilized Supra G NIR Conformer NIR Express II
Stent size (mm) 3.0–3.5 3.0–3.5 2.5, 3.0, 3.5
Stent length (mm) 15 18 15 16, 24, 32
Polymer — Translute Translute Translute
p Value p Value
Trial arm
No. of patients 59 60 30 31 136 131 — 652 662 —
Drug coating — Paclitaxel — Paclitaxel — Paclitaxel — NA Paclitaxel —
Drug dosing — 3.2 g/mm2 — 1.0 g/mm2 — 1.0 g/mm2 — NA 1.0 g/mm2 —
Diabetics (%) 17 18 13 23 16.0 11 0.159 25 23.4 0.52
Complex lesions (B2/C) (5) 8 8 43 29 — — — — —
Mean lesion length (mm) 10.5 10.9 11.9 10.7 10.51 10.55 0.93 13.37 13.38 0.980
Stents per patient — — — — — — — 1.09 1.08 0.740
6 Months 6 Months 6 Months 9 Months
Angiographic data
Reference vessel diameter (mm) 2.88 2.94 2.94 2.99 2.77 2.78 0.920 2.75 2.75 0.930
Late loss in-stent (mm) 1.04 0.29 0.71 0.36 0.79 0.31 0.0001 0.92 0.39 0.001
Late loss insegment (mm) — — — — — — — 0.61 0.23 0.001
Late loss index — — 0.45 0.22 0.53 0.22 0.001 0.61 0.23 0.001
Diameter stenosis at baseline (%) — — 57.8 56.5 62.8 63.3 0.680 65.6 66.5 0.110
Diameter stenosis at FU (%) 39.0 14.0 27.2 13.4 31.8 19.5 37.2 17.4 0.001
Restenosis, in-stent (%) 27.0 4.0 10.3 0 17.9 2.3 0 24.4 5.5 0.001
Proximal restenosis (%) — — — — 2.2 1.6 1.00 3.4 2.7 0.810
Distal restenosis (%) — — — — 3.0 1.6 0.685 1.9 0.7 0.270
Restenosis, in-segment (%) — — — — 20.1 5.5 26.6 7.9 0.001
IVUS data
No. of patients 25 28 26 26 125 118 87 91 0.650
Neointimal volume (mm3) 31 13 22 15 — — — 41 18 0.001
Volume obstruction (%) — 10.6 7.2 22.2 7.8 0.001 29.4 12.2 0.001
Clinical data
Death (%) 0 0 — 0.8 0 1.00 1.1 1.4 0.80
MI (%) — — — — — — — 3.7 3.5 0.88
Q-wave MI 0 0 — — 1.5 0 0.498 0.3 0.8 —
Non–Q-wave MI 0 2.1 — — 3.8 1.5 0.447 3.4 2.7 —
CABG (%) 0 0 3.3 0 0.8 0.8 1.00 3.1 0.6 0.001
Thrombosis (all) (%) 0 0 0 0 0 1.0 — 0.8 0.6 0.750
Acute thrombosis (24 h) — — — — 0 0.8 0.491 0.3 0 —
Subacute thrombosis (1–30 days) — — — — 0 0 — 0.3 0.3 —
Late thrombosis (30 days) — — — — 0 0 — 0.2 0.3 —
TVR (all) at FU (%) 4.1 2.1 6.7 0 14.3 7.7 0.114 12.0 4.7 0.0001
TLR (in lesion) at FU 6.7 0 12.0 4.6 0.043 11.3 3.0 0.0001
TVR (remote) at FU 0 0 2.3 3.1 0.720 1.1 1.7 0.480
MACE at FU (%) 4.1 4.2 6.7 0 19.5 8.5 0.013 15.0 8.5 0.0002
TVF (%) — — — — — 14.4 7.6 0.0001
Abbreviations as in Tables 1 to 3.
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Year in Interventional Cardiology March 3, 2004:875–90ilterWire EX patients and 11.6% of GuardWire patients
difference 1.7% [95% CI 6.4% to 3.1%], p  0.53 for
uperiority, p  0.0008 for non-inferiority). This was the
rst study to demonstrate that distal embolic protection
ith a filter system provides a level of protection equivalent
o that of the GuardWire balloon occlusion system. Based
n these results, the FilterWire Ex System was approved by
he FDA for use in SVG intervention.
The TRAP trial, which is the only superiority designed
lter study, compared the efficacy of stenting with or
ithout the TRAP vascular filtration system (56). The trial
as started before any protection devices were commercially
vailable in the U.S., but had difficulty with patient enroll-
ent once the GuardWire System was approved for clinical
se. This ultimately led to early termination of the study
fter 360 of 460 planned patients had been randomized.
he primary end point of the study—30-day MACE—was
ot significantly different in either treatment group; how-
ver, there was trend toward a lower incidence of MI in the
RAP group, with a relative reduction similar to that seen
n the SAFER trial (Fig. 2). Several non-inferiority trials
ith other filter systems are currently in progress and will
ompare the investigational device to either the FilterWire
ystem or GuardWire device.
hrombolysis/thrombectomy. Because most SVG lesions
ontain a significant thrombus burden, several devices have
able 5. Trials of Other Coronary Devices
Study Design
istal protection
FIRE (55) PCI in SVG lesions; randomized to PCI
with FilterWire or GuardWire system
TRAP (56)* PCI in SVG lesions; randomized to PCI
with TRAP system or PCI alone
hrombolysis and
thrombectomy
ATLAS (57) Patients with ACS and SVG lesion;
randomized to PCI with acolysis or
abciximab
X-TRACT (58) Patients with SVG or thrombus-
containing native coronary artery;
randomized to adjunctive
thrombectomy with X-SIZER or no
device before stenting
overed stents
RECOVERS (59) PCI in SVG stenosis; randomized to
PTFE-covered stent (JoStent) or bare-
metal stent
STING (60) PCI in SVG lesions; randomized to
PTFE-covered stent (Jostent) or
conventional stent
Trial stopped early due to poor patient enrollment.
ACS  acute coronary syndrome; PTFE  polytetrafluoroethylene; SVG  sapeen designed to reduce and/or remove thrombus before stent implantation, in the hope that this will lessen the risk
f embolic complications. Coronary ultrasound thromboly-
is uses an acolysis probe to deliver low-frequency ultra-
ound at the treatment site, which will lyse or liquefy
hrombus to subcapillary size. Initial results suggested this
evice would be a promising mechanical adjunct in SVG
ntervention. In the multicenter Acolysis during Treat-
ent of Lesions Affecting Saphenous vein bypass grafts
ATLAS) trial, patients with ACS undergoing SVG lesion
reatment were randomized to receive either acolysis or
bciximab (57). However, the Data and Safety Monitoring
Primary End Point Results
MACE at 30 days
(death, MI, and
TVR)
PCI with FilterWire resulted in
similar rate MACE to PCI with
GuardWire (9.9% vs. 11.6%,
p  0.0008 for non-inferiority)
MACE at 30 days No significant difference in primary
end point, but underpowered
due to early termination trial
Procedural success
(diameter stenosis
30%, TIMI flow
grade 3, and freedom
from MACE
Lower rate of procedural success
and higher MACE in acolysis
group
MACE at 30 days No difference in overall MACE at
30 days or 1 year; lower rate of
large MI in X-SIZER group
Angiographic restenosis
at 6 months
Higher 30-day MACE in PTFE
stent group due to higher rate
MI; no difference in incidence
restenosis
Binary restenosis at 6
months
Restenosis rate 29% with PTFE
stent vs. 20% conventional stent
(p  0.15)
vein graft; other abbreviations and acronyms as in Tables 1–3.
igure 2. Incidence of major adverse cardiac events (MACE) and myo-
ardial infarction (MI) at 30 days in the Saphenous vein graft Angioplasty
ree of Emboli Randomized (SAFER) and TRAP vascular filtrationn
651
360
181
797
301
211ystem (TRAP) randomized trials.
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March 3, 2004:875–90 Year in Interventional Cardiologyommittee stopped the trial prematurely, after 181 patients
ere enrolled, because of a higher incidence of adverse
vents in the acolysis arm. At 30 days, the cumulative
ncidence of MACE was 25% in the acolysis group and
2.4% in the abciximab group, mainly due to a higher rate
f MI in the acolysis group. Use of the X-Sizer (ev3,
lymouth, Minnesota) thrombectomy device was studied in
he X-SIZER for TReatment of thrombus and Atheroscle-
osis in Coronary intervention Trial (X-TRACT) (58).
wo-thirds of patients had a SVG lesion. Overall, the
ncidence of periprocedural MI was similar in device and
ontrol patients, and there was no major clinical benefit with
hrombectomy at one-year follow-up. However, the rate of
arge infarction (creatine kinase-MB fraction 8  upper
imits of normal or new Q waves) was reduced with the
-SIZER device, especially in patients with visible throm-
us. These data suggest that adjunctive thrombectomy with
he X-SIZER device reduces the extent but not the occur-
ence of periprocedural myonecrosis.
overed stents. Two randomized trials (Randomized Eval-
ation of polytetrafluoroethylene COVERed stent in Saphe-
ous vein grafts [RECOVERS] and STents IN Grafts
STING]) have evaluated the role of a polytetrafluoroethylene-
overed stent in SVG intervention (59,60). The JoStent
oronary stent graft (Jomed, Sweden), which was used in
oth studies, has a sandwich-like design with a polytetra-
uoroethylene membrane between two stainless-steel stents.
t was proposed that the membrane would entrap debris and
laque during stent implantation, thus reducing embolic
omplications, and also reduce neointimal proliferation
hrough the stent mesh. At six months, the incidence of
inary restenosis (the primary end point in both trials) was
imilar between the polytetrafluoroethylene stent graft and
onventional bare-metal stent groups. Moreover, in the
ECOVERS trial, there was a higher incidence of in-
ospital and late myocardial infarction in the polytetrafluo-
oethylene stent group, whereas the STING trial demon-
trated a trend toward a higher rate of late occlusion in the
tent graft group (16% vs. 7%, p  0.069). These studies
herefore indicate that routine use of the JoStent in SVG
esions does not confer any additional benefit over bare-
etal stents. Other coronary stent grafts, with easier de-
loyment techniques, are presently under clinical investiga-
ion and may have a more favorable outcome given the
ignificant differences in stent design.
ONTRAST NEPHROPATHY
he year 2003 brought mixed results in efforts to reduce
ontrast nephropathy after PCI. Gruberg et al. (61) re-
mphasized the adverse prognostic impact that impaired
enal function has on in-hospital and one-year survival.
hey analyzed in-hospital and one-year mortality in 1,265
atients undergoing PCI of SVG lesions. Patients with a
reatinine clearance 30 ml/min had a 7.1% versus 0.3%
n-hospital and 7.1% versus 36.7% one-year (p  0.01) Tortality compared with patients with a creatinine clearance
70 ml/min. Similarly, Qureshi et al. (62) found that
mpaired renal function was associated with a twofold
ncrease in the risk of death in a large institutional data base.
spelin et al. (63) randomized 129 patients with impaired
enal function (serum creatinine of 1.5 to 3.1 mg/dl) to
irect arteriography with iodixanol or iohexol. Fewer pa-
ients (3% vs. 26%, p  0.002) had contrast nephropathy
ith iodixanol (serum creatinine increase of 0.5 mg/dl vs.
aseline). Conversely, Stone et al. (64) found in the pro-
pective, randomized, placebo-controlled, multicenter trial
valuating fenoldopam mesylate for the prevention of
ontrast-induced nephropathy (CONTRAST trial ) that
here was no impact of the type of contrast agent used on
adiocontrast-induced nephropathy. More importantly, the
ONTRAST trial conclusively demonstrated that fenoldo-
am pretreatment had no benefit in prevention of RCIN,
ith 28% versus 24% (p  NS) of active treatment versus
ontrol treated patients developing serum creatinine in-
reases 0.5 mg/dl. Marenzi et al. (65) randomized 114
atients with creatinine 2 mg/dl to control versus post-
rocedural hemofiltration. The incidence of RCIN (increase
f serum creatinine 25% of baseline) was reduced from
2% to 9% (p  0.001). In addition, hospital mortality was
educed (2% vs. 14%, p 0.001). The main criticism of this
rial is that the contrast dose in both patient groups
ppeared to be excessive (258 ml).
The benefit of acetylcysteine has been extended to urgent
rocedures by the use of an intravenous formulation admin-
strated as an intravenous bolus in the RApid Protocol for
he Prevention of contrast-Induced renal Dysfunction
RAPPID) study (66). The incidence of RCIN was reduced
rom 21% to 5% (p  0.045) in this randomized trial of 80
atients. Finally, an intriguing pilot study employing a 2:1
ilution of gadolinium and iohexol was reported by Sarkis et
l. (67). In total, these studies suggest that acetylcysteine or
emofiltration may ameliorate the problem of RCIN. It
ppears that more effective, easier to use methods of renal
rotection still need to be developed.
IABETES MELLITUS AND PCI
ith the looming epidemic of diabetes and coronary artery
isease, the year 2003 brought further study into diabetic
atients undergoing PCI. Marso et al. (68) reviewed the
id America Heart experience with PCI from 1980 to
999. They found that diabetic patients had an almost
wofold increased risk of in-hospital death after elective or
rgent PCI. Outcomes appear to be improving for elective
ut not for urgent cases. Muhlstein et al. (69) found an
xcessive risk in undiagnosed diabetics who had only mild
levations of fasting glucose levels. Similarly, Corpus et al.
70) found that mild elevations of hemoglobin A1c were
ssociated with increased risk of death and target vessel
evascularization in undiagnosed “prediabetic” patients.
hese two studies demonstrate that impaired glucose toler-
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nd this has definite adverse consequences. Mazeika et al.
71) demonstrated that poor glycemic control increased the
isk of restenosis in diabetic patients. Recognition of occult
iabetes and optimal glycemic control is critical, since
akagi et al. (72) demonstrated that pioglitazone decreases
ntimal proliferation in diabetic patients. As Piatti et al. (73)
uggest, insulin resistance plays a role in restenosis in
iabetics. In aggregate, these studies are a continued call to
ction for aggressive screening for occult diabetic patients
nd aggressive glycemic control after PCI.
DJUNCTIVE PHARMACOTHERAPY
lopidogrel has become a mainstay agent to limit subacute
hrombosis after stent implantation. In 2003, an alternative
ethod to decrease stent thrombosis was presented with
wo studies evaluating heparin-coated stents (74,75). Meh-
an et al. (74) randomized 200 patients to treatment with a
eparin-coated stent and aspirin alone or aspirin and clopi-
ogrel. No difference in the incidence of subacute throm-
osis was observed between the groups. This stent may be
articularly useful in patients who cannot take clopidogrel or
n whom antiplatelet therapy must be stopped quickly (i.e.,
rgent noncardiac surgery). The most important advance
oncerning clopidogrel was the Intracoronary Stenting and
ntithrombotic Regimen-Rapid Early Action for Coronary
reatment (ISAR-REACT) trial (76) (Table 6). In this
tudy, 2,195 elective PCI patients were randomized to a
00-mg oral loading dose of clopidogrel or abciximab
herapy. No difference in MACE occurred. This study
uggests that when elective PCI patients can be loaded with
00 mg clopidogrel, there may not be a need for intravenous
P receptor blockade.
able 6. Trials of Adjunctive Pharmacotherapy
Study Study Design
REST (85) Patients undergoing stent implantation
(bare metal); randomized to
cilostazol or placebo for 6 months
RUISE (83) Patients undergoing elective or urgent
PCI; randomized to either
eptifibatide  enoxaparin or
eptifibatide  unfractionated
heparin
SAR-REACT (76) Patients undergoing elective PCI; all
received clopidogrel 600 mg (2 h
before PCI); randomized to
abciximab or placebo
EPLACE-2 (80) Elective or urgent PCI; randomized to
intravenous bivalirudin with
provisional GP IIb/IIIa inhibition
or heparin with planned GP IIb/
IIIa inhibition (abciximab or
eptifibatide)
I  confidence interval; GP  glycoprotein; MLD  minimal lumen diameter; OThe pharmacokinetics of oral loading of clopidogrel ieceived intense scrutiny in 2003. Although oral loading of
00 mg in elective cases led to excellent outcomes in the
SAR-REACT trial, a 75-mg loading dose appears insuf-
cient (77). In fact, Mueller et al. (78) found that ticlopi-
ine (500-mg bolus and 250 mg twice daily) resulted in a
ower mortality than clopidogrel (75-mg bolus and 75
g/day) in a randomized trial of 700 patients. Grubel et al.
77) found that great patient variability occurs with respect
o platelet inhibition after 300 mg oral loading dose. Muller
t al. (79) reported that statin therapy did not alter platelet
nhibition after a 600-mg oral loading dose of clopidogrel.
n aggregate, these studies suggest that a clear dose-
esponse curve exists for oral loading of clopidogrel. A
oading dose of 75 mg is clearly inadequate. Based on the
SAR-REACT trial, a new standard loading dose of 600
g orally at least 2 h before planned intervention appears
ecessary.
A second major advance in PCI pharmacotherapy oc-
urred with the publication of the Randomized Evaluation
f Percutaneous coronary intervention Linking Angiomax
o reduced Clinical Events (REPLACE-2) trial (80). In this
rial, 6,010 patients undergoing PCI were randomized to
reatment with bivalirudin and clopidogrel or heparin plus
P receptor blocker and clopidogrel treatment. A higher
isk of bleeding was seen in the GP IIb/IIIa group, whereas
slight increased risk of post-PCI creatine kinase elevation
ccurred in the bivalirudin group. This trial suggests that, at
east in low-risk patients, bivalirudin and clopidogrel may be
n effective alternative to GP IIb/IIIa as an antiplatelet
egimen.
The use of GP IIb/IIIa came under further scrutiny with
he publication of the New York State experience (81). In
his large community database, GP IIb/IIIa appeared to
Primary End Point Results
5 MLD by angiography
at 6 months
Cilostazol resulted in larger MLD
(1.81 vs. 1.67 mm, p  0.0188)
and lower binary restenosis
(20.8% vs. 34.6%, p  0.0006)
at 6 months
1 Bleeding index (change
in hemoglobin
corrected for blood
transfusions)
Similar rate of vascular access
complications, bleeding and
angiographic complications in
both study groups; no difference
in MACE at 48 h or 30 days
5 MACE at 30 days No difference in death/MI or
MACE
0 Composite of death,
MI, urgent repeat
revascularization, or
in-hospital bleeding
Incidence of composite end point
similar in both groups (9.2%
for bivalirudin group vs. 10%
for heparin group; OR 1.09,
95% CI 0.90–1.32; p  0.40)
odds ratio; other abbreviations and acronyms as in Tables 1 to 3.n
70
26
2,19
6,01ncrease adverse outcomes. However, as Klein and Calvin
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March 3, 2004:875–90 Year in Interventional Cardiology82) point out, extrapolation of outcomes from tightly
onitored clinical trials to the “real world” may not be
ppropriate. In addition, high-dose heparin therapy may
ave been the problem in the New York experience. In this
ein, the Coronary Revascularization Using Integrilin and
ingle-bolus Enoxaparin (CRUISE) trial suggests that ju-
icious dosing of either heparin or enoxaparin will result in
ow rates of bleeding complications in patients undergoing
CI with concomitant GP IIb/IIIa therapy (83). Further-
ore, the National Investigators Collaborating on
noxaparin-3 (NICE-3) trial also found that combined
herapy with enoxaparin and GP IIb/IIIa was associated
ith a low bleeding risk in 628 patients undergoing PCI
84). In summary, optimal antiplatelet therapy (oral or
ntravenous) and optimal antithrombotic therapy (heparin,
noxaparin, and bivalirudin) have been extensively tested.
o doubt, the year 2004 will bring numerous further studies
ith these combinations.
Cilostazol, a platelet-aggregation inhibitor, appears to be
beneficial adjunct for patients who are treated with a
are-metal stent during coronary revascularization. In the
ulticenter Cilostazol for REStenosis Trial (CREST),
atients assigned to cilostazol therapy had a significant
eduction in angiographic restenosis at six months (85).
mportantly, a benefit was also seen in diabetics and those
ith small vessels. This is the first oral agent that has been
hown to successfully reduce restenosis after stent implan-
ation.
UTURE ADVANCES
umerous studies have attempted to delineate procedural
isk after PCI (62,86,87). These studies suggest that ad-
ances in computerized databases may play a major role in
uture outcome research. The year 2003 also ushered in the
awn of new diagnostic imaging modalities (88–90). These
tudies suggest that multi-slice computed tomography and
able 7. Upcoming Interventional Cardiology Trials in 2004
Topic Acronym
cute myocardial infarction AIMI
AMI-HOT
EMERALD
cute coronary syndromes SYNERGY
rug-eluting stents SISR
TAXUS VI
ENDEAVOR II
ENDEAVOR III
REALITY
FUTURE III
aphenous vein graft intervention BARRICADE
CAPTIVE
GUARD
SYMBIOT
CI  percutaneous coronary intervention; SVG  saphenous vein graft; other abbardiac magnetic resonance imaging will emerge as alterna-ives to invasive coronary angiography. If this occurs, a
evolution in screening for coronary artery disease, assess-
ent of coronary progression and regression, and studies of
estenosis and bypass graft patency will occur. In addition,
he year 2003 brought the dawn of alternatives to radiog-
aphy as a prerequisite for therapeutic intervention. Faddis
t al. (91) have demonstrated that catheters, designed to be
anipulated by magnetic fields, will allow interventions
both coronary and intracavitary) to occur with minimal
-ray exposure. Finally, cell transplantation is emerging as a
romising approach to cardiac repair in acute and chronic
schemic heart disease (92,93).
The year 2004 will bring a variety of new clinical trials in
MI, ACS, DES implantation, and vein graft interventions
Table 7). We anticipate as difficult a task in 2004 as we
ave had in 2003 in summarizing advances in this rapidly
volving field.
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